Enhancing Week-long Psychological Treatment for PTSD With Ketamine
Phase 2
162
about 8 years
21–70
1 site in CT
About this study
This trial is testing if a combination of ketamine, midazolam, and intensive trauma-focused psychotherapy will be more effective in treating post-traumatic stress disorder (PTSD) than usual care. The goal is to see if this week-long treatment can provide significant relief that would normally take months to achieve. Researchers are also studying the brain changes caused by this clinical trial.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ketamine
- 2.Take Midazolam
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), midazolam (Benzodiazepine; short-acting)
injection
Primary: To determine if ketamine + exposure therapy results in clinical improvement in PTSD symptoms which are significantly greater than midazolam + exposure therapy (Phase 2; combined R61/R33 data)
Secondary: Change from baseline to 90 days post treatment in Beck Depression Inventory (BDI-II)
Psychiatry / Mental Health